Global Ovarian Hyperstimulation Treatment Market, By Type (Surgery, Chemotherapy, Radiation, Biological Therapy), Grades (Mild (Grade 1 and Grade 2), Moderate (Grade 3), Severe (Grade 4 and Grade 5), Diagnosis (Physical Exam, Ultrasound, Blood Test), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Ovarian Hyperstimulation Treatment Market Analysis and Size
Ovarian Hyperstimulation may occasionally occur unexpectedly, the majority of cases are because of controlled ovarian stimulation (COS) in women undergoing assisted reproductive techniques (ART) therapy. The exact cause of this condition is currently unknown and is controversial; however, ovarian response is directly associated with risk of ovarian hyperstimulation. Higher estradiol levels occurring in such a scenario are necessary but are unlikely to be high enough to cause ovarian hyperstimulation. The main characteristics of ovarian hyperstimulation are increased vascular permeability and ovarian enlargement.
Data Bridge Market Research analyses a growth rate in the ovarian hyperstimulation treatment market in the forecast period 2023-2030. The expected CAGR of ovarian hyperstimulation treatment market is around 5% in the mentioned forecast period. The market was valued at USD 5.7 billion in 2022, and it would grow upto USD 8.42 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Ovarian Hyperstimulation Treatment Market Scope and Segmentation
2022 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type (Surgery, Chemotherapy, Radiation, Biological Therapy), Grades (Mild (Grade 1 and Grade 2), Moderate (Grade 3), Severe (Grade 4 and Grade 5), Diagnosis (Physical Exam, Ultrasound, Blood Test), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Cook Group (U.S.), The Cooper Companies Inc (India), Genea Biomedx (Sydney), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.)
Ovarian hyperstimulation is a syndrome in which patients witness iatrogenic complications associated with reproduction. The ovarian hyperstimulation is identified by cystic enlargement of the ovaries combined with fluid shift from intravascular to the third space caused by the capillaries' increase in permeability. This syndrome is associated with typical physical and psychosocial morbidity and has been related with maternal death.
Global Ovarian Hyperstimulation Treatment Market Dynamics
- Huge Success Rates of Injectable Fertility Medications
Injectable fertility medications includes hormones such as follicle stimulating hormone (FSH) and lutenizing hormone (LH). A huge success rate has been witnessed with FSH that will depend upon the reason for using it. For instance, if FSH is used strictly for patients who are not ovulating, and are devoid of any infertility factors, then success rates approach to 60-70% after 3-6 IUI cycles. If FSH or IUI is used in patients as empirical therapy to increase the likelihood of pregnancy, then success rates are around 30% after 3-4 cycles. That is, one in three women completing 3-4 cycles of “empiric” FSH/IUI therapy will achieve pregnancy. This boost the market growth.
- Increased Treatment Procedures
There are several treatment procedures that are available which are boosting the growth of the market. Stimulation of multifollicular development in women include ovarian stimulation as part of treatment along with assisted reproductive technologies (ART). In addition to this, luteinizing hormone (LH) is found to be in association with follicular stimulation in women suffering from severe LH and FSH deficiency. Thus, several types of stimulation procedures are included for varied treatment types.
- Presence of Increased HCG Hormones During Pregnancy
The high level of hormone which is produced during pregnancy known as human chorionic gonadotropin (HCG) will be a raising factor of several ovarian hyperstimulation diseases and would likely to create much opportunities for the global ovarian hyperstimulation treatment market growth. It has been witnessed that ovarian blood levels react abnormally to HCG hormone and causes leakage of the fluid that further leads to swelling in the ovaries. Sometimes, it may even move to the abdomen. Thus, these factors crate opportunities for the market growth.
- Rising Healthcare Awareness
Health awareness amongst the population is increasing, which results in the production of drugs to boost the market growth. The innovative launches in terms of medications for the treatment of ovarian hyperstimulation diseases are expected to increase the market growth simultaneously. Several researchers are investing in launching the drugs that benefit the market. This creates more opportunity in the market.
- Lack of Skilled Professionals
Lack of trained healthcare professionals who are unaware of the treatment methods for this disease could limit the growth of the global ovarian hyperstimulation treatment market over a forecast period.
- High Cost
The huge expenditure of the treatment methods hamper the market growth. The high cost associated with the varied hyperstimulation treatment types are hampering the market growth.
This ovarian hyperstimulation treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the ovarian hyperstimulation treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Ovarian Hyperstimulation Treatment Market Scope
The ovarian hyperstimulation treatment market is segmented on the basis of type, grades, diagnosis, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Biological Therapy
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Grade 5
- Physical Exam
- Blood Test
- Speciality Centres
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Ovarian Hyperstimulation Treatment Market Regional Analysis/Insights
The ovarian hyperstimulation treatment market is analyzed and market size insights and trends are provided by type, grades, diagnosis, distribution channel and end-user as referenced above.
The major countries covered in the ovarian hyperstimulation treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the presence of key product manufacturers, increasing research and development activities and healthcare expenditure.
Asia-Pacific dominates the market due to increased new research and developments on ovarian related diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Ovarian Hyperstimulation Treatment Market Share Analysis
The ovarian hyperstimulation treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to ovarian hyperstimulation treatment market.
Key players operating in the ovarian hyperstimulation treatment market include:
- Cook Group (U.S.)
- The Cooper Companies Inc (India)
- Genea Biomedx (Sydney)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Fresenius Kabi AG (Germany)
- Amneal Pharmaceuticals LLC. (U.S.)